The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.
 
Esmail Mutahar Al-Ezzi
No Relationships to Disclose
 
Abhenil Mittal
No Relationships to Disclose
 
Brooke Wilson
No Relationships to Disclose
 
Marco Iafolla
Honoraria - Bayer Health; Canadian Urological Association (CUA); CompassMD; Ipsen; MD Analytics; Merck; Save Your Skin Foundation; Sermo
Consulting or Advisory Role - Novartis
Research Funding - Astellas Pharma; AstraZeneca Canada; Bristol-Myers Squibb
 
Pavlina Spiliopoulou
No Relationships to Disclose
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Nazanin Fallah-Rad
No Relationships to Disclose
 
Peter W. M. Chung
Honoraria - Abbvie; AstraZeneca; Boston Scientific
Consulting or Advisory Role - Tersera; Verity Pharmaceuticals
Research Funding - Abbvie
 
Nathan Perlis
No Relationships to Disclose
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)